References
- Foerester J, Paraskevas F. Multiple myeloma. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rogers GM, editors, Wintrobe's clinical hematology. Baltimore: Williams & Wilkins; 1999. p 2631 —2680.
- Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol/Oncol Clin North Am 1999;13:1259–1272.
- Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 1991;47: 262–267.
- Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med 1975;135:87–93.
- Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994;12: 2398 — 2404.
- Sinclair D. IgD myeloma: clinical, biological and laboratory features. Clin Lab 2002;48:617–622.
- Sinclair D, Cranfield T. IgD myeloma: a potential missed diagnosis. Ann Clin Biochem 2001;38:564–565.
- Homan H, Ohtubo Y, Ito H et al. IgD multiple myeloma with renal involvement: case report. Japan J Med 1990;29:212 — 215.
- Kyle RA. IgD multiple myeloma: a cure at 21 years. Am J Hematol 1998;29:41–43.
- Takemori N, Kondo K, Kawamura T, Imai K, Sakurai H, Sato T. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment. Am J Hematol 2001;66:62— 63.
- Fukuno K, Tsurumi H, Yamada T, Oyama M, Moriwaki H. Complete remission of plasmablastic IgD lambda multiple myeloma induced by continuous infusion of low-dose cytarabine and etoposide. Rinsho Ketsueki 2000;41:513–518.
- Wechalekar A, Amato D, Chen C, Stewart AK, Reece D. IgD multiple myeloma — a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol 2005;84:115–117.